Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | GRM5 | P41594 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | STAT3 | P40763 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.40 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26288734 | 0.88 | HTT (0.47) | LIPEL3MBTL1GRM5HTTPKM | |
| SCHEMBL29872143 | 0.84 | LIPE (0.53) | LIPEL3MBTL1GRM5HTTPKM | |
| SCHEMBL23460224 | 0.84 | LIPE (0.53) | LIPEL3MBTL1GRM5HTTPKM | |
| SCHEMBL19007909 | 0.80 | L3MBTL1 (0.51) | L3MBTL1GRM5HTTPKMSTAT3 | |
| SCHEMBL29957302 | 0.78 | MAPT (0.39) | HTTSMN1; SMN2ALDH1A1MAPTMAPK1 | |
| SCHEMBL15515593 | 0.78 | PKM (0.49) | L3MBTL1GRM5HTTPKMSTAT3 | |
| SCHEMBL30939981 | 0.78 | PKM (0.49) | L3MBTL1GRM5HTTPKMSTAT3 | |
| SCHEMBL23274021 | 0.78 | NUDT1 (0.49) | L3MBTL1HTTPKMSTAT3SMN1; SMN2 | |
| SCHEMBL16805396 | 0.78 | L3MBTL1 (0.49) | L3MBTL1GRM5HTTPKMSTAT3 | |
| SCHEMBL27827736 | 0.77 | NOX1 (0.56) | L3MBTL1GRM5PKMSMN1; SMN2NOX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018162-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | NURIX THERAPEUTICS, INC. | 2024-01-18 | — | — | US | disclosed |
| US-20230145336-A1 | BRAF DEGRADERS | C4 THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230145336-A1 | BRAF DEGRADERS | BRAF, NRAS, RAF1 | LIPE 3411/4885L3MBTL1 1385/4885GRM5 4299/4885 |
| US-20240018162-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | TTK, HIPK1, CLK1 | LIPE 2298/4885L3MBTL1 699/4885GRM5 4371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.